Proposals of statistical consideration to evaluation of results for a specific region in multi-regional trials - Asian perspective

Pharmaceutical Statistics

Volumn 9, Issue 3, 2010, Pages 201-206

  Tsou, Hsiao Hui ^a   Chow, Shein Chung ^b   Gordon Lan, K K ^c   Liu, Jen Pei ^a,d   Wang, Mey ^e   Chern, Herng Der ^e   Ho, Low Tone ^f   Hsiung, Chao A ^a   Hsiao, Chin Fu ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e Center for Drug Evaluation   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Bridging study; Ethnic effect; Multi regional trials; Similarity

Indexed keywords

ASIA; CLINICAL TRIAL; DRUG EFFICACY; EUROPE; EVALUATION; REGISTRATION; SHORT SURVEY; STATISTICAL ANALYSIS; UNITED STATES;

ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CONTROLLED CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; GEOGRAPHY; HUMANS; INTERNATIONALITY; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; POLYMORPHISM, GENETIC; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 77957365760     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.442     Document Type: Short Survey

References (12)

1. ICH, International Conference on Harmonisation. Tripartite guidance E5 ethnic factors in the acceptability of foreign data. The U.S. Federal Register 1998; 83:31790-31796.
2. Ministry of Health, Labour and Welfare of Japan. Basic Principles on Global Clinical Trials 2007.
3. ICH, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Q&A for the ICH E5 guideline on ethnic factors in the acceptability of foreign data 2006. Available at: http://www.ich.org/LOB/media/MEDIA 1194.pdf.
4. Kawai N, Chuang-Stein C, Komiyama O, Ii Y. An approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Information Journal 2008;42:139-147.
5. Quan H, Zhao PL, Zhang J, Roessner M, Aizawa K. Sample size considerations for Japanese patients based on MHLW guidance. Pharmaceutical Statistics 2010, early view.
6. Uesaka H. Sample size allocation to regions in multiregional trial. Journal of Biopharmaceutical Statistics 2009; 19:580-595.
7. Ko FS, Tsou HH, Liu JP, Hsiao CF. Sample size determination for a specific region in a multi-regional trial. Journal of Biopharmaceutical Statistics 2010; in press.
8. Caraco Y. Genes and the response to drugs. The New England Journal of Medicine 2004; 351(27):2867-2869.
9. Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, Eddy SM, Dostalik J, Mount J, Azuma J, Fujio Y, Jang IJ, Shin SG, Bleavins MR, Williams JA, Paulauskis JD, Wilner KD. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clinical Pharmacology & Therapeutics 2008; 84(3):347-361.
10. Chung WH, Hung SI, Hong HS, Hsih M S, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428(6982):486.
11. Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S. Strong association between HLA-A* 0206 and Stevens-Johnson syndrome in the Japanese. American Journal of Ophthalmology 2007; 143(2):367-368.
12. Lin M, Chu CC, Chang SL, et al. The origin of Minnan and Hakka, the so-called 'Taiwanese', inferred by HLA study. Tissue Antigen 2001;57:192-199.